This relative benefit seen in the combined population is strikingly similar to that reported from the EBCTCG meta-analysis3,41 in which a slight improvement in DFS and OS was seen with the use of anthracyclines in a mixed pool of breast cancer patients unselected for HER2 status. Here, ERBB2 is linked to breast carcinoma.